CBD-Intel

Business briefing

ValidCare reports to US FDA that trials find no evidence of CBD liver toxicity

Written by || 23rd March 2021 || Business briefing | Health | North America United States

No evidence of liver toxicity from CBD has been found in the ValidCare study, the results of which have been given to the US Food and Drug Administration (FDA) for review ...

Restricted content. Do you want to read more?

Read related content from CBD-Intel

CBD industry steps up with funding for ValidCare’s vital liver function study
Pregnant mice study touches on FDA questions, but more research is needed
It’s not toxic – but is CBD effective? That’s the question for research team

Featured topic

The Food and Drug Administration (FDA) rejected applications to use hemp extract as a dietary supplement.

Here are the conclusions we have attracted. CBD-Intel will continue to work on providing answers to the various questions that have arisen.

Blog | Policy and politics | US federal regulation

Sign up to our newsletter

By signing up you agree to our Terms and Conditions